Jefferies analyst Anthony Linton maintained a Buy rating on Tourmaline Oil (TOU – Research Report) today and set a price target of C$78.00. The ...

Tourmaline Oil Corp. closed 7.6% below its 52-week high of C$70.83, which the company reached on February 21st.

Tourmaline strategically pivoted from natural gas to liquids production amid pricing challenges. See why we believe TRMLF ...

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total ...

Tourmaline Bio (NASDAQ:TRML – Get Free Report) had its price objective lifted by analysts at HC Wainwright from $49.00 to $50.00 in a research report issued on Friday,Benzinga reports. The firm ...

Tourmaline Oil Corp. closed 8.2% below its 52-week high of C$70.83, which the company achieved on February 21st.

TOURMALINE BIO ($TRML) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.86 per share, beating estimates of -$0.89 by $0 ...

Readers hoping to buy Tourmaline Oil Corp. ( TSE:TOU ) for its dividend will need to make their move shortly, as ...

Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued on Thursday, March 6th. Wedbush analyst L. Chico expects that the company will post ...

NEW YORK - Tourmaline Bio, Inc. (NASDAQ: TRML) reported a wider fourth quarter loss on Wednesday, as the clinical-stage biotech company ramped up spending on research and development. Shares fell 2% ...